Bea van der Kleij

Learn More
Sixty-two patients with uncontrolled partial seizures participated in a 12-week, double-blind, placebo-controlled add-on-trial. Thirty-two patients received loreclezole and 30 a placebo as add-on therapy. Loreclezole was targeted at a plasma level of 1-2 mg/l. In spite of an antiepileptic therapy, usually with 2 or 3 antiepileptic drugs, these patients had(More)
The effect and safety of loreclezole were evaluated during a long-term follow-up trial targeting higher plasma concentrations than those of the preceding controlled trial. The result is better than in the double-blind trial, in which loreclezole doses were administered to reach plasma concentrations of 1-2 mg/l and 6/32 patients (19%) of the verum group(More)
thiamine deficiency, while Group V was normal. The fat contents were 2.1 4O. I8"$/0 for Group IV; 4.3 4o.93~/o for Group V and 3.7 4o.44~/o for Group VI. These figures demonstrate tha t both Groups V and VI had synthesized fat from carbohydrate (P values for differences with Group IV < o.o 5 and < o.oi respectively). Their mutual difference has no(More)
BACKGROUND Crushing solid oral dosage forms is an important risk factor for medication administration errors (MAEs) in patients with swallowing difficulties. Nursing home (NH) residents, especially those on psychogeriatric wards, have a high prevalence of such difficulties. CONTEXT Six different psychogeriatric wards in two Dutch NH facilities,(More)
  • 1